Compare Asana Inc. (ASAN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Asana Inc. trades at $9.11 (market cap $2.13B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 63× Asana Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | VRTX | |
|---|---|---|
Market Cap | $2.13B | $134.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $529.65 |
52-Week Low | $5.46 | $376.62 |
Enterprise Value | $1.96B | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
